<SEC-DOCUMENT>0001193125-12-506176.txt : 20121218
<SEC-HEADER>0001193125-12-506176.hdr.sgml : 20121218
<ACCEPTANCE-DATETIME>20121218130804
ACCESSION NUMBER:		0001193125-12-506176
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20121217
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20121218
DATE AS OF CHANGE:		20121218

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AP PHARMA INC /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		121270709

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d456464d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM&nbsp;8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act
of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>December&nbsp;17, 2012 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>A.P. PHARMA,
INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Charter) </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-33221</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-2875566</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>123 Saginaw Drive</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Redwood City, CA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94063</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code:&nbsp;(650)&nbsp;366-2626 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see</I> General
Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01&nbsp;Other Events. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On December&nbsp;17, 2012, A.P. Pharma, Inc. (the &#147;Company&#148;) announced the appointments of Joel Schaedler as Vice President of Market Access and Daniel Martin as Vice President of Marketing.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01&nbsp;Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit&nbsp;No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:72pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Document Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release issued on December 17, 2012</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. PHARMA, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: December&nbsp;18, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John B. Whelan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d456464dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g456464g36e62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For Immediate Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma Makes Key Appointments in Preparation of Potential FDA Approval of Lead Product Candidate, APF530 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>&#150; Joel Schaedler named as Vice President of Market Access &#150; </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#150; Daniel Martin named Vice President of Marketing &#150; </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">REDWOOD CITY, Calif. &#150; December&nbsp;17, 2012 &#150; A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Joel Schaedler as vice president of
market access and Daniel Martin as vice president of marketing. Mr.&nbsp;Schaedler will be responsible for the Company&#146;s market access programs for APF530, the Company&#146;s lead product candidate for the prevention of chemotherapy-induced
nausea and vomiting, if approved. Mr.&nbsp;Martin will lead the marketing efforts for APF530. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The strategic expansion of our executive
team is critical as we continue to prepare for potential marketing approval for our lead product candidate, APF530,&#148; said John B. Whelan, A.P. Pharma&#146;s president and chief executive officer. &#147;Joel and Dan bring uniquely specific
experiences that will be vital to our pre-commercialization activities and success surrounding the potential launch of APF530. We welcome them to the team and look forward to working with them on the marketing and market access program that are key
to the Company&#146;s future.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">About Joel Schaedler </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Schaedler brings over 17 years of specialty pharmaceutical and healthcare distributor experience to A.P. Pharma. Most recently, he was the senior vice president of business development at P4
Healthcare, which was acquired by Cardinal Health in 2010. Prior to his tenure at Cardinal Health, Mr.&nbsp;Schaedler was the regional vice president of sales for Bionicare Medical Technologies where he focused on the development of marketing
strategies, physician targeting and creation of operational efficiencies. He has also held positions of increasing responsibilities with Amerisource Bergen Specialty, Centocor (acquired by Johnson&nbsp;&amp; Johnson) and Sanofi-Aventis.
Mr.&nbsp;Schaedler has a bachelor&#146;s of arts degree in business administration from Kent State University in Kent, Ohio. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>- more - </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B><I></I><I></I><I></I><B></B><I></I><B></B><I>A.P. Pharma Makes Key Appointments in Preparation of Potential FDA Approval
of </I><I></I><I></I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Lead Product Candidate, APF530</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Page&nbsp;
 2
</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">About Daniel Martin </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Martin brings 14 years of diverse health care industry experience and nearly nine years of oncology marketing experience to A.P. Pharma. Most recently he was the head of US marketing at Dendreon,
reporting to the executive vice president and chief commercial officer. Prior to joining Dendreon, Mr.&nbsp;Martin spent 7 years in positions of increasing responsibility within Amgen&#146;s Oncology Business Unit. Mr.&nbsp;Martin worked on
Amgen&#146;s Aranesp<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and Neulasta<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> franchises and then led the launch of
XGEVA<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> into both oncology and urology. Prior to these roles, Mr.&nbsp;Martin led strategic planning and
operations for Amgen&#146;s oncology GPO team. Prior to Amgen, Mr.&nbsp;Martin worked as a management consultant with Deloitte Consulting where he specialized in pharmaceutical marketing and commercial operations. Mr.&nbsp;Martin holds a
bachelor&#146;s of arts in economics and biology from the University of Virginia and received his master&#146;s in business administration from the University of Pennsylvania&#146;s Wharton School of Business. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About APF530 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma&#146;s lead
product, APF530, is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). One of the most debilitating side effects of cancer chemotherapy, CINV is a leading cause of premature
discontinuation of treatment. There is only one injectable 5-HT3 antagonist approved for the prevention of delayed-onset CINV, so this indication represents an area of particular unmet medical need. APF530 contains the 5-HT3 antagonist granisetron
formulated in the Company&#146;s proprietary Biochronomer&#153; drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. This five-day range is designed to cover the delayed
phase of CINV, whereas currently available intravenous and oral formulations of granisetron are approved only for the prevention of acute-onset CINV. Granisetron was selected for APF530 because it is widely prescribed by physicians based on a
well-established record of safety and efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About A.P. Pharma </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma is a specialty pharmaceutical company developing products using its proprietary Biochronomer&#153; polymer-based drug delivery platform. This drug delivery platform is designed to improve the
therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks. The Company&#146;s lead product, APF530, is being
developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. A.P. Pharma resubmitted its New </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>- more - </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">



<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="4%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B></B><I></I><I></I><I></I><B></B><I></I><B></B><I>A.P. Pharma Makes Key Appointments in Preparation of Potential FDA Approval
of </I><I></I><I></I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Lead Product Candidate, APF530</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Page&nbsp;
 3
</FONT></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Drug Application (NDA) for APF530 to the U.S. Food and Drug Administration in September 2012 and has been assigned a Prescription Drug User Fee Act (PDUFA) action date of March&nbsp;27, 2013. For
further information, please visit the Company&#146;s web site at <U>www.appharma.com.</U> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward-looking Statements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This news release contains &#147;forward-looking statements&#148; as defined by the Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve risks and uncertainties, including uncertainties associated with the potential approval of APF530 and the potential timing for such approval, if approved at all, as well as risks relating to capital resources and
liquidity, satisfactory completion of clinical studies, progress in research and development programs, launch and acceptance of new products and other risks and uncertainties identified in the Company&#146;s filings with the Securities and Exchange
Commission. We caution investors that forward-looking statements reflect our analysis only on their stated date. We do not intend to update them except as required by law. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Relations Contact: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Rice </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 646-597-6979
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email: <U>mrice@lifesciadvisors.com</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A.P. Pharma, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John B. Whelan, President and Chief Executive Officer </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Phone: 650-366-2626 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>### </I></FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g456464g36e62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g456464g36e62.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*0!^`P$1``(1`0,1`?_$`*X```$$`@,!````````
M```````%!P@*!@D!`@0#`0`!!0$!`0$``````````````00&!P@%`P()$```
M!@(!`P$%!`8*`P`````!`@,$!08'"``1$@DA,5$3%!5!(C(6\&&!L7(7<9&A
MP=%"LG.S-28V"A$``@`%`P(%`@,$!PD``````0(1`P0%!@`A$C$'05$B$PAA
M<8$R%/!R(Q61H;'10F(6@C-38R0T-387_]H`#`,!``(1`Q$`/P"_OUZ<-&N.
M\OO_`'\0GC&/A^WX_AH,%,#UUI[W0\S^K6JDE)TBL.'&>,N1IE6CRIT*09DK
M=;D4Q,46MQO9RNXR.<H*"'Q6C--\]3]0.FF/+S[?_'W.<]277NJVZPN=ITX$
M,PV,43\Q!'0D`'P)UGON1\E,#[?3)EMDNUROJ#>3)(*(VX@\S\H((W`B80Z1
MU7=S5YU=],IO72=-L]2P77EC&*A%8YK<?(2R*/</9\U:[DA.2+AQV#]Y1NBS
M((^P@>G-88]\7^WEJ1?YH*FOJ5/J:8W%&^R)`0\H[^>L991\L>YMYJ&_E,Z3
M;*)AZ4E(&9?.+L"T?QAMMJ,;+R@>0F.=MY%';7+JRS94JR:+Z4AY!F<Y1_"Y
M8/X1TQ<HF$?4BB9B#[N3U^QG:.9):2UDI`2L.2<D<?C'4$E_(7N_(GJR7VK<
M@Q]4&4_3B=6$_%%YBK?LKD".UJV;:P?\S)R.?.L=Y+K[%&#8W1Y#M%7[^L6:
M"1/\A'64\<@HY:N&0)MG145$Q124`@J9#[X=@*?!:!\JQ3FUC2!GR6;F\OD>
M*LK&!*EMB-R/MK9/83Y(56<7-,0S`(M\F1%/.1>*S2JEBCJ-@W$;$``PWW.K
M%I!*!0#NZ^GM'^O[/3F7!T'EK8G4<@-OIKL)RAZB(![?[`Z_NY\EE#<#^:$?
MPTG4P\8PT=Q>O3KT'IU]0$/3W^H<^X'1]?`:.XOO^SK^SGP'5C`'?21WAXZ.
M\OOXO)?`C0#'IH[B^_\`3_'BZ6(\QH[B^SK^_A]-)$>8UR!@$1`!]0]OZN$"
M!'PT1'F-`F`/:/3K[^(#$$CPT$@=2!H[@]_$#J02/#2]/QU\%U2I%$ZARID(
M0ZACG,4A"%3#N.<YS"!2D(4!$1$0#IQ=]R-S#IYGP_NU\LP01Z'S/0#Q.JWF
M[.V^UV]#V^:Y>-RL3CW$]2D7%7S3LTRL411ZS894A!1>T.GWZP2,/&L84#+`
M1XY:+G?R'4I40(U/\1QJCMO@V#]O?TV3=XYT;M/0/34'%ICJI$5FS),L,_VB
ML-MXG88[[C]P<^[D/6XIV:DC^24K%*NX,ZR49HP,J7-FLB`0AT8DC?8$1J_[
M`:XYHU=OQL8YTH[RB6X(IM.LF2[R,E8^7@WR[E%O,PDW"O'\7,,%GC59,RJ2
MHB55,Y3@!@YN?#LOQK,[.+EBU2*BWRB4;T-+]ME`)E\&"LL`RF!$=XZP/FV%
M9/@]Y-KRJG:1<)BB8"7$P3%8D"8)BEE8$@B()$1#2CKQJYG3:NRV6HX&I*EX
MGZC5'-TGF!)6)B1;0+5VW8&505EWC)%Z^</'2:2#5(PKKG'H0H]!Z-\NSW%<
M$HY-PRJI_2T=1-$N6Q28W)SO""*Q'U)@!YZ]\,[=95G]344>+TWZJJI91F3%
M#RU*IY^ME!WV@(F,-M]/#FWQQ[BZ\8F8YMRKBHD/CE=>/92LI%6NK6=[47LF
MH1!DWN<97Y60=5XZSM8C<PG[R(.3E25,0Y@+S@XYWC[=Y7?1CEDKS,N[`E4:
M3.E!N,8\7F(J&$#L#O#;;4CR;LCG^(X[_JF]4(EVL%066=)F%2_Y0R2YC.L?
M'D!#H8'7Q\;K&8DM]-1VL"58T@&;Z@].=`IC&1BXQ=:2FE3]OL1)"LW/Q/L^
M'W=?3GCWKJ*5.UU\ES@K`T3;GH&B0@!\RQVAI.Q,NHG=V[&*8D5"UZ;"/Y1'
MF?P7KJY#EKR[Z287N^3<;6Z\W!U?<43`P5FJU;QU:Y]\O))%,,B2&<-6/TM^
MV@^@`]<"NFW;&$"F/W"`<_/2S=DNX][M-#>*.DDBWU\L-)=YTI`PZ?XG!!)!
M@"(G7Z87OOOVUL%VK;-5U=0UTH'X3I<N1-?@WW"<2/J"1I\*KNMA++VJ&0-K
M<0V@M@H=-I=_FWJSYBYB).%G*37G<J_@9R+>D2=1TJ@)4NI!ZE.FL0Z9C$.4
MPQNNP6_X_F=-B60R&DW:;.DIQV8%9S@*0REA`CKOMXZD=O[B8YD>"5>:V&H]
MRV2:><_(J5*M*EDD%6`((V^A\#K19XU?*5@;6S6*-)LQE7,%]R5DK*ELLUGD
M2PUVR5'XYBWR[*(@(J=LTFNJPATU6D0K($C62KAP1!QW_`+U]="]UNRN2Y)F
M\ZFPVAI9=GI*1$$L-*E/.*K%G"!N1)VBS*(GQUFSM'WVQK',(ESLVK:N==ZN
MXS"S\)DR7*1W]"F81P`&XXJQ('AK?IL-N7K_`*PX]JV1LI6]PWB;\NT9X[B:
MS"RMIM&0I!^Q;R31A3Z]$M5WTFNJP=)JB(@FD0ARB<Q>X`'.&,X3D>6W"?:K
M93#]52!C.YNLM)(0P)F.Y55W$!$[PVUJ#*^XF,8;:9%YO$YC2U3*)'"6[M-+
M@%>"H"3$$;]!'3=:G^0[7_<"UW?'N.4<C53(N/F#67LE"RG1WU'M#>(=N461
M)))FZ<.T5$$7;E(BI!4(LF*R8F3[3E,/8S#MAE.#4-/=;RE,]KJR5E3I,Q9D
MMF`C#DI._P#;#7%P/NYBO<2NJ+3:Q4R;M2IRF29Z&6ZJ3`&'3RVZC;34L?+K
MJ%,973P?!2E\FLH.\WH8#B*PQJ'<O.6T9@\'(ST<Y4DB-@H\(^)T<R2PIE$!
MZ(D5,!@+T:KLCG=%9%R*KDTTNRFA_5-,::`/;*Q0")B6;IQ4$CQUQ*3OQ@=?
M?WQ>D>J>_+7?I!)5`6]P-Q8F$0%7<\V@"!$:P_(?FBU`Q_;,NT+Y'-%RN>&;
M),5FRP-(QFXGS/U*X[>L;)/1<@C(IQJ56KSQ@9-T_>J,TRF.7M`WJ)7UI["Y
MQ<J*BN?*WTELKI*3);SJA5CSAP'$GF8DP@JGZZYUX^1&"6>XUUI$NX5=UM\U
MDF))D%P#+)YGF/0(`$[D&`UBMD\ZNE43082_P,=FZ]QS]NV7M#2IXP=KCC-9
MR[59(1609N1D8^K1$XZ41$[9JB_='<)"4Y.I3D[NG2_'3N)-O4VQU#4-/6H6
M""94(#.XJ&)DI$M"!_,RA?#3"?\`)OMNMJEW>D%?4T\SB)@2G<"3R)7^),("
M=1T5B8:FYES>'`F&<!T/8JV2]D>TC*+:K*8SC:S4Y>Q7&\2-TC"3%<@82N,4
M!6^LOF)Q-\-P=N0ABB4Q^H``UY9\"R2^9'4XK2"5_,*5I@FLTQ4ERQ*8K,9G
M)"\5(ZB,?`:LJ^=R,9L.*4N85?O3+95K+,E$EL\UVFB**J@&!/\`F@!YZBA4
M?+YB2W_S6A6NOFV,;E#$]:K]TD<+RN)"(Y0LE5G[?5:B$O6(!&=<&=FBU;>U
M?N45S-S?32*K)BH"9@"9U_9&]T`H:M[C9WLM=,F2UK%G_P#3I,ERGF%)C].1
MX%%(B.975?T'R"L5>M=3+:;XE\H94N::1I(]^9*>=+E<T2,8+[@<@P/`-",(
M:C%YY=ZY/!^+(363&LTO$7_-T+(2-\FV"ZB$C5\1HKJQ[IFV51$%6LA?GZ*S
M(IRB50K!LZ`OWE"&"=_&;MG3Y;D#99=I2S;1;ID)8;\K5$"P9@=F26!NOBQ7
MRU"/E1W2JL3LDO#;%,*7RXRXS&5H,L@GAQ4QBK.T=]H*IWWUJQKFE^/=?*%K
MKB;82)VDV(R=M4G`Y/K.K>";&^H^(::QEP8PK2R9%L:3*;7?6F)C)$"NE&38
MGR22:G<8J1"+*6[=^X]TS"Z7B]XT;%;+595FR7KZR6DRJGE%B94I"0R*=^$(
MCH!OL*?LG;*W8?9;59<O-^NETO?MSUH**8TNDE*Q$)DYP&#N(#EL"/$CKI9\
MO..LG[&[WH8&UVQQ9,C%UBUPQ[674+52_5WT1"F[YUV^E7KYTD8Z+)O9XUN9
M14_Q#*>INHB(\]/CW>K)AO;,Y7E59)I:>\W2<\@MZ?=:$M/2!UB4,/"'VTT^
M1U@O>:]S1C.(4<RK-GM4B6ZIZC+1>4R+$^0F`1/4_4Z\7CBKMYQKXZO)9L'2
M(.T2-ZG:_!80I1J@QDW]@:=[8`LTO%C"%6D"!#DOB#I1=$!^"#/O[@`O4%[U
M7.AO?=C$L4NTZ3+M$L_J)JS"H0<O5+8EMCRX0`/VUX=C[7=+'VAR_*[1*J&N
MTZ6M+):6I+B!/N[#<<.0)(Z;:7<$X]REB3Q+9XHMRK=G/D;?#,U,QOK7B":1
M<-+9:7R2T"66L\;`31VSEHF_3CW*QG"@)`8C-!4Y@!5,QF677?&,@[\VRY69
MZ<6+'*)WKZJ5Q62J[GU,@XEEB%@-R8CP.NIBULR:P_'^XVZ]RZAK[D=?+E4%
M-,#-.F,"`2J-ZEY$1!.W2&Q&I#^%GQ_Y'PIEK+.SFR]&D<>*81A9NH4V!GS,
M#O`L4C!-Y2Z6HJC%T]8JLX.I+%9I*D5,47#Y<O4#(&`(U\B>Z5FRNRT.'X54
MK4TMQG^[->7&`3GQDI$P,6<%B(1$`>AU(?C7VBO6(7JX9QF]*U+46Z2\N6CP
MY%^)>8\-Q!9;05@=R?II?\5NR&N6.L.[X;AYQO\`C=C=<EYDN=E>UJ=E816]
MOZL+!W8(*`CH!VJ:<?HV^:LSA!%N@F=-P*)>_P#`(@P[U8KEUQO6,83C]#7+
M:Z:W2%$R6LSV#.>'N.77TJ4XQB8&!^NNMV.R[#+79,ISS(ZRB:YU5PFO[<PR
MS.]M.7!5EMZF#%H>F(VWZ:8"I(6W7/P39[MEBAW-9E=P<S":CUQ=,S59.F71
M_7XY!=HR`Q13;2]7J$BJW```%&9DE`ZE,'667"HH,Q^2UMIZ91/H[!0H:AE]
M7KI58L6/CP<J(QW;4:I4K\1^,]TKJV-/4Y%</X$L[12>4@%&T`Z*Q^VI'>1+
M&K/&7CX\=FC%7BVC&RYFR'ANOS+9DR30=.I:/@6)K5*N`;D(HH[7N5T;&57-
MU4.`=!$?7D'[3W%KYW*RON/4SF:DMM'5S4=F8*`682E/^R!!?H-2_NY9J>R=
MJL4[;4$J5+JKG5TB3):A>;-!6FM&$8^XY!;\(PU(G9?<BWN]JR:*X2R%@36F
M`USQ["6Z][(Y[AX*Q/*PLQK<,#.*Q17[,Z8P1;$RK<\W#XZAS+'*=;L^&1+J
MK&L3P*4N"OW,OM/<[K,NE4\J50T9=8GF>35+H&8RRP)"PZ$1B>DKS#N)5C.9
M7;+'ZRU6F5:Z57FUU:J/`K+4*M,CD!74'J.I!Z>,9O%_='9\L>3_`'EM^5I+
M-C+&].7J,-F*<BHZN+9"BZE&3-E2FTX>,21BXIH]@:7#@V;I%`$FZJ11ZB(]
M9GWGD(MDPKMM1T,JAF5<WWS2(SNTJ9,8`JSMOU9XGS!U!^R57,-\S3N7<KA,
MN4JBDO(EU;*J>ZJ`MRX+``^A>(\CJ0WA>QQ3<3Z)W?<>]5>"<9%OLQF#*4U>
M9&.:+SZ%-IRTK\M&-)5RF=RRC%).%D'@D1,F515UW'[A`HA$_D#=ZV\=S*7`
MZ!YLNUT<FDHDE!C[8F&$"5'40==]^D/'4P^/5FM=D[8U7<FYR),R]U3U54\]
ME!F%)8;HQW!9E.PAU\=1'U-G%L.>&G>#;&9*W:W[8ZRY5393SI)$L@\3MDDT
MQK'().S]5U6Z=BG95R5/N[0.!C=.OKR:9Q1S+SW_`,:P*F(%%:)-,&@29<9*
MB>T5Z+LL#J!X-._TY\?LGSZH4"X7J?4<(@<_XS>P!RZF)=C^$=>'9FJK8/\`
M"7ISKC"MD(R][2W;&IY1JU;$(\F7-ODW>3'!W94RE4<K(.7<,U$3B)@(!"!Z
M```ZQ6XS,H^15_S"IFDT5FIZH@F)4)*3V5XKTA&)^Q)\]>694"8Q\;\?QBGE
M!:V^5%*6XCU%II]\Q(W)@0N\=_3J7VT6W%GQ7GO$?CFQ5E_$^I]2QGA>GSV0
MMD<KP\)-G@6T%5TP@X#&\'9E&]93L*D:R(HDY6$5#N%#E2$@H&^)!<+P2AO.
M)W#NU=*&LO-557.;*DT%,[J#,9RS-4,GK]F/4+L0(G8ZGN:Y]76/(;?V@M%?
M1V&DHK9*FS[A4(C$!47TTX>*^[#H3O$F'36NW7.W'L&8?(9LX^W,RNK3<=0N
M`,,PNYYXB*4N:$'?,_8QBUK8E5_HHQB%;185UTE\C\CT^BNS#V]YN[EIY?1?
MI;%B6&2[!1BMJ?U]8]L$QO:9THJB8$9N4>>W*/+\ZCP.JCQ*Z-59%E>:3,EJ
MVM]+*HJ)+H98]U4FW"EEF8J0@4X@J?\`*Q\M07\O]XF;SY%-DCS(G,E4IZOT
M"%;*B84VT%6Z?")H))E'[I47;I\X<B`!ZF<&'[>HVW\=+736[M+:_9$)<\S9
MSP_QL[D-'[`0&J?^25UGW+O'=5KB62G9)4L#JJHB\8'PBT6.L"8^3C?2+I=.
MQ_&;,7R-K-#1AF]<1CTH!G*I-*[\M]$CI*PH0Q)R:BF9&B:9FSI=5)=(@$6!
M0OISIS.Q7:ZHNU5=*JURG:IY14LY6+Q+-QY!0T28$"(CMU.N(G?ONI+ME/:I
M%VGRJ>EX++*A0P1=@I>'(@`#8F&P'339Q.Z>TT%D3*F6X/,=BB\DYMB4H+*-
MM:,J\G)6^*1:HLB,'0&AE6L>D1HW(4OR:;8?N%'KU`!#OS>V&`UEJH,<K*%&
MM5M9GIT+L>#$\H@1WB8QB3'7`D=U<[HKQ6W^FN4Y+G<$*U,P`!IBGTA3]``.
MD(>'34YXG>R,U[\<>NF$M7\NV.J;&-,W6C*^8'U=C9J*6K:#A.R-HN"<2<G&
M%@+0SD&#B-1<-@^;0.5N('+]T.5+_P#,*C,^[EUR3-+8)N)_H12TJ&!,PJ%`
M:(8-+*'D0PZ1$([ZN?\`^O4F$]F;/C^#W!ERPUSU%04!!0'[CBP;8$,?#IIV
MM"<&[V^238^E[,9.S/DB&I>)I8BQ,XR'R:+YNX;`H5U3<)Q*T:6MMY1\1<Y'
MKUNS^4CRF%13XKD$T^<7NMDO;/L_B=1@./T%*]PN$L%Z80<<H>B94322YAL1
M+W#0Z@;Z[7:/'.Z7>7,:?.+Y<:R306]XK5-'H#ZI=.D`BMN07$.,8^J&K6.V
MU6R=8=4LXT3"T1^8LGVK%MCI--9/9AC&*/)&RQYZ^H^>S4LNT9)KMF+]5R=5
M50HJ*)_:8P!S#^'55EHLOH:^^M[5JE5B39O`1]"'D0JCZB``VAK?6>4%ZK,*
MN%LQU?>NDZB>3*YL`2[KPY,Q(\-R8QCMJ#>H/B9ULI^OFO3;8C77&5KSY1*L
M"ENFI9NG,_\`D3Z>D["K'2JD<\&"M[>#5D0;(&=INDRII`!![.@<LC.N]>97
M/*+G4XI=ZR1C=741EHCE0)84+Z01%20-P(;DZJSM[V(PZV8A;)64VBDFY532
MB9C.`\9A=F]7$\7"Q$(QUL=RQKOA?.M>KM1S!C:JW^KU&;C['6H"<9G/$P\W
M$M5F4:_9L6QV[=-1BS<'22*)1(5,PE`O0>G*ILV29#8*J;6V6JG4E7/1DF.C
MDM,1_P`RL2(P;QU<EYQ;'\CHY5#?Z2154TB8KRU98++91!2H!\!M#I#;IKT7
M?`.'LEW''>0<@8XJEMNF)9!25QI89IA\X_I,DLLT<*O8`YA*1HX,O'H'[NT1
M`R11#IVASSH+_?K91U-NH*F;)H*X0J):N>,Q1&`.V_U!_KT7#&+#=*RFN%?1
MT\ZNH6Y4TQE]4HDQ,/*$!#[>>F[R/I+JAE[([/+N3]?\7WS)#%&/02MEHK;:
M5?+I1`B,4$B@N`Q\L:._"B9TBL9,@`4!Z``<[%ISS-;!:FLMCN572VPDGVY<
MPJ`3U(/41^GCOKDWKMS@^1747N]VJBJKH%`,R9+Y$@=`5C!H>$8ZR:OZKZ\5
M.E7W&]7PSCJOT'*3MX^R-3XBML6%>NKJ10(U?J3\6W23;/!=-4RIF`0Z=A0+
MTZ>G&-5E63W&Y4UWN5?53KI2*!)G,Y+J!T@8>&_CI]0X9BELM539:"W4DJU5
MG(SI*+Q1RWF!_<(>&LVC,.8MA<8AA>(H%4C<3!7WU5_ETSB&K>H_ER4*X+(P
M@PR:96@QKT':H*I=O:I\0W4/4>,IUWNU3=&O5543)EV,Q7]XDF9R6'%H]8B`
M@8^&GU-C]FH[0MAIJ:5+LHE,GL`?P^+1Y+#Q!B8QZQUC+[6G`$EBEA@M_AK'
M#O#44L@XC<8.*I$JTAFX;2*LN@JC73-OII#I2BYW`#\/J"QA-[1XZ&3Y(+NU
M^%;4B\O^:?[A]UHB#`MUW7;KIH^(8RUF3'C0TQLDN'&04'M*5,5/'IL=^FEF
MTX*P]=_R!^<,842S_P`J7C21QH$[6HN3+1'S`C)-BZJI7394L(NS3C6X)'0`
MAB`@3I^$.-:2^7ZW_J30U<^5^L!6?Q<CW58'DKPZAB8GKX^>G55CEBKA2BKI
M*>8*$JU/R0'V7001D!V'$;#RT@9$UBUYRY:H:\Y2PABO(=PKZ2+>'LERI,#8
M9=DV;K'<-FR;R38.5%&S9=0QTTS]Q"&,(E`!$>KNU9/DUEH9ELM-?64U!,)+
M2Y<YPK$]280W^NF%WPG$[_72[G?+=15=PDPX3)DE6<0Z")\!Y&(TK16OF#()
ME:8Z%PYC")CKS-Q-CN<?'4BN,V%KGX&30FH2:L+-"-(VEY.(EVJ;ELLN0YT5
MTRG*(&`!!)N29%/G2JF=7U35,B6R2W,QBZ!E*,%:,5!4D&'4&'37M)Q+&*>E
MG4,BW424-0ZM,EB4@1^+!U++"!*L`PCL"`=5G_-AXR<Q67,,OMS@2GRN1H*Z
MQ403+--JK,\E;*U8:[&-H5&WQT`U(:0GH.:AF+<KL&A%G#1PW,H8@I*B8FO_
M`(Y=YK%:+(,&RJI6FG2YI--,F$+**.=T+G\K!H0CL8['8C6)_D_V.R&YWM^X
M.*4YJJ::BBHE2P6G!UV#A`#R4CRW!ZB!!U69?0LU%NUX^4AI>,?ME3(N6,A&
M/F3ULJ0PE,DX9NFZ+E!0I@$!*<H&#W<V9)O-IJ)(J)553-(/1A-0@_8@[C6'
MIUFN]//:FFTM2L]#`J9;A@?(@B(T_>']1=H,^.VS+$6!LGW5)RJ1,)9C5))C
M6FXJ]@`H]M4TC&UMD@7_`#&4=%``]_(U?^Y&"XS(>;>[I0RUX14"8'F$[[*J
MQ)Z?TQU*,<[99[E52)%BM=7.9C`L9;++`\RY``A&)WV&K"6F/_SY.&TE$7[=
M*V1SY!HLW>I80H#Y1RS<J(J@J#.\7PA$3.69Q3*"S&+3`BI>I1=B41*.3>XG
MRKF5]*]K[?RIDHNO!ZN:(,1_RI?A^\T#'_#K8W;'X@I2SY=T[CS9;F6P9:60
M25)'_&<CI_E2/CZATU9ZK%4KE+K\/5*E!0]9K-?8HQ<%`0,>UBHB(C6Q`3;L
MHY@S21;-6Z28``%(4`_;U'F-JNHJ:^J:NK7:=6.Q)=R68D^))W)UN.CH:.WT
M:6^WRTD44M0JH@"J`/``?L?'2Z8G<`EZ]`']7K^G7G@RQ!X'BY\>NG0`$!`%
M8=#OKDA>PA2^GH'V!T#V^[BB,-S$Z`("&WX"`_HUWXNET<-&CAHT<-&CAHT<
M-&CAHT<-&CAHUT/^(G\7]P\:U'^\E_O:/V_J.HX7K_VV0_@;?\7+#L__`(M/
MNW]NJJNW_L$W]X?V:?F(_P"H8_["/^@O('=OSG]_5BV7_LT_'2N7[?Z>?0_*
J/L-/E\?OKMQ=?6CAHT<-&CAHT<-&CAHT<-&CAHT<-&CAHT<-&CAHU__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
